Seeing Is Believing
Currently out of the existing stock ratings of Difei Yang, 225 are a BUY (91.84%), 19 are a HOLD (7.76%), 1 are a SELL (0.41%).
Analyst Difei Yang, carries an average stock price target met ratio of 52.62% that have a potential upside of 46.93% achieved within 477 days. Previously, Difei Yang worked at MIZUHO, AEGIS, BREAN.
Difei Yang’s has documented 509 price targets and ratings displayed on 38 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on MGTA, Magenta Therapeutics at 18-Apr-2022.
Analyst best performing recommendations are on RLYP (RELYPSA).
The best stock recommendation documented was for RLYP (RELYPSA) at 7/18/2016. The price target of $26 was fulfilled within 3 days with a profit of $5.75 (28.4%) receiving and performance score of 94.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Dec-2019
$13
4 years 1 months 6 days ago
(29-Aug-2022)
1/6 (16.67%)
$4.7 (56.63%)
176
Buy Since 07-Nov-2019
$20
4 years 1 months 11 days ago
(24-Aug-2022)
0/5 (0%)
$14.21 (245.42%)
Buy Since 09-Jan-2020
$29
4 years 1 months 11 days ago
(24-Aug-2022)
0/2 (0%)
$14.55 (100.69%)
Buy Since 17-Sep-2015
$14
4 years 1 months 12 days ago
(23-Aug-2022)
7/19 (36.84%)
$7.75 (124.00%)
211
Buy Since 22-Oct-2019
$15.25
$62
4 years 1 months 12 days ago
(23-Aug-2022)
1/2 (50%)
$0.09 (0.59%)
48